Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38621400
3.
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
Ann Oncol
; 2024 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38754780
4.
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
J Urol
; : 101097JU0000000000004010, 2024 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38758680
5.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Eur J Nucl Med Mol Imaging
; 51(2): 558-567, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37736808
6.
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
BJU Int
; 133 Suppl 3: 39-47, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37604702
7.
Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
BJU Int
; 133 Suppl 4: 14-22, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37858931
8.
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Eur J Nucl Med Mol Imaging
; 50(8): 2529-2536, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36905411
9.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37246997
10.
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
BJU Int
; 131(5): 588-595, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36371669
11.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36261050
12.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33581798
13.
The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
Ann Surg Oncol
; 29(5): 2871-2881, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35142966
14.
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.
Eur J Nucl Med Mol Imaging
; 49(9): 3289-3294, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35298693
15.
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
BJU Int
; 130 Suppl 3: 32-39, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35488182
16.
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Radiology
; 299(2): 248-260, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33787338
17.
Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
Ann Surg Oncol
; 28(8): 4561-4569, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33393039
18.
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(2): 477-482, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32696091
19.
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Eur J Nucl Med Mol Imaging
; 48(5): 1626-1638, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33604691
20.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34028967